Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2016
Event: Discontinuation of clinical development for revusiran, an investigational RNA interference therapeutic for hereditary ATTR amyloidosis with cardiomyopathy.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
- Development Status: The Company decided to discontinue the development of revusiran.
- Catalyst: The decision follows a recommendation from the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing.
Outlook, Risks, and Management Commentary
Management Commentary: The discontinuation was a direct result of the DMC's recommendation to suspend dosing in the ENDEAVOUR Phase 3 study. No further guidance or outlook regarding future financial performance is provided in this specific filing.
Risks and Contingencies: The filing highlights the risk of clinical trial failure and the subsequent halt of a specific drug candidate. The text notes that the information in Item 8.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the statements made.
Investor Verification Checklist
- Verify the specific findings of the ENDEAVOUR Phase 3 study Data Monitoring Committee that led to the suspension of dosing.
- Assess the impact of discontinuing revusiran on the Company's overall pipeline and future revenue projections.
- Review the full text of the Press Release (Exhibit 99.1) for additional details on the DMC's rationale.
- Check subsequent filings for any updates on the Company's strategic direction following this discontinuation.